BCL2L1 and melanoma: In particular, resistance to MAPK inhibition based on high levels of antiapoptotic Bcl-2 proteins was overcome in melanoma cells by another small molecule BH3 mimetic (TW-37) developed by computer modeling for binding to Mcl-1, Bcl-xL and Bcl-2 [141].